Steven Seedhouse
Stock Analyst at Raymond James
(3.22)
# 2,106
Out of 5,178 analysts
170
Total ratings
46.63%
Success rate
0.72%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Upgrades: Outperform | $23 | $10.91 | +110.82% | 4 | Mar 13, 2026 | |
| DNTH Dianthus Therapeutics | Upgrades: Strong Buy | $63 → $123 | $82.45 | +49.18% | 5 | Mar 10, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $9.56 | +171.97% | 2 | Oct 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $88.88 | -7.74% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $6.20 | +61.29% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $27.47 | +1.93% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.93 | +975.27% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $34.25 | +203.65% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $7.14 | +208.12% | 2 | Dec 11, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.50 | +833.33% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $136.88 | -32.06% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $40.26 | +68.90% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $17.64 | +500.91% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.69 | +163.62% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $18.55 | +201.89% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $13.24 | +330.51% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $6.04 | +264.24% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.32 | +632.76% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $4.69 | +646.27% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $80.18 | -52.61% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.37 | +1,234.04% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $64.99 | -41.53% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $7.08 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | - | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.59 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $13.50 | +1,900.00% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $191.06 | - | 2 | Apr 23, 2020 |
Korro Bio
Mar 13, 2026
Upgrades: Outperform
Price Target: $23
Current: $10.91
Upside: +110.82%
Dianthus Therapeutics
Mar 10, 2026
Upgrades: Strong Buy
Price Target: $63 → $123
Current: $82.45
Upside: +49.18%
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $9.56
Upside: +171.97%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $88.88
Upside: -7.74%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $6.20
Upside: +61.29%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $27.47
Upside: +1.93%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.93
Upside: +975.27%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $34.25
Upside: +203.65%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $7.14
Upside: +208.12%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.50
Upside: +833.33%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $136.88
Upside: -32.06%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $40.26
Upside: +68.90%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $17.64
Upside: +500.91%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.69
Upside: +163.62%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $18.55
Upside: +201.89%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $13.24
Upside: +330.51%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $6.04
Upside: +264.24%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.32
Upside: +632.76%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $4.69
Upside: +646.27%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $80.18
Upside: -52.61%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.37
Upside: +1,234.04%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $64.99
Upside: -41.53%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $7.08
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: -
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.59
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $13.50
Upside: +1,900.00%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $191.06
Upside: -